TP53 and head and neck squamous cell carcinoma: This therapy, called Gendicine, is a recombinant human p53 adenovirus created by Shenzhen SiBiono GeneTech, and it was authorized in 2003 by the China Food and Drug Administration (CFDA) for the treatment of head and neck squamous cell carcinoma (HNSCC).